Abfero Pharmaceuticals
Innovative oral iron chelators targeting diseases of iron overload with a focus on neurodegenerative and retinal disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $225m Valuation: $225m | Acquisition | |
| Total Funding | 000k | ||
Related Content
Abfero Pharmaceuticals is a biotechnology company dedicated to developing advanced oral iron chelators aimed at treating diseases caused by iron overload. The company operates in the pharmaceutical and healthcare market, focusing on conditions such as neurodegenerative disorders and age-related macular degeneration (AMD). Abfero's core product, SP 420, is designed to safely and effectively reduce iron accumulation in the body, particularly in the brain and retina. This innovative approach has the potential to slow the progression of diseases like Parkinson's and AMD, which are significant causes of disability and blindness. The company serves patients suffering from these conditions and collaborates with healthcare providers and research institutions to advance its treatments. Abfero's business model revolves around the research, development, and commercialization of its proprietary iron chelation therapies. Revenue is generated through the sale of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Keywords: iron chelators, neurodegenerative disorders, retinal disorders, SP 420, AMD, Parkinson's, biotechnology, healthcare, pharmaceutical, innovation.